Amneal Pharmaceuticals(DE:2DT)
€19.30+0.60 (+3.21%)
DE:2DT
Amneal Pharmaceuticals financials statements
€19.30
At close:+0.60 (+3.21%)
Amneal Pharmaceuticals (2DT) Income Statement
2 Followers
Amneal Pharmaceuticals Income Statement
Last quarter (Q3 2026), Amneal Pharmaceuticals's total revenue was $862.68M, an increase of 9.96% from the same quarter last year. In Q3, Amneal Pharmaceuticals's net income was $-7.46M. See Amneal Pharmaceuticals’s key income statements, including revenue, expenses, profit, and income.
| Income Statement | Dec 25 | Dec 24 | Dec 23 | Dec 22 | Dec 21 |
|---|---|---|---|---|---|
| $ 3.02B | $ 2.79B | $ 2.39B | $ 2.21B | $ 2.09B | |
| $ 1.14B | $ 1.02B | $ 863.87M | $ 791.46M | $ 768.97M | |
| $ 713.00M | $ 771.11M | $ 659.50M | $ 886.39M | $ 616.26M | |
| Depreciation and Amortization | $ 223.57M | $ 236.19M | $ 229.40M | $ 240.18M | $ 233.41M |
| $ 603.87M | $ 439.77M | $ 500.78M | $ 440.21M | $ 401.10M | |
| $ 423.09M | $ 249.33M | $ 204.37M | $ -94.93M | $ 152.72M | |
| $ -283.88M | $ -304.34M | $ -244.64M | $ -153.20M | $ -121.35M | |
| $ 139.21M | $ -55.01M | $ -40.27M | $ -248.13M | $ 31.37M | |
| $ 72.06M | $ -116.89M | $ -83.99M | $ -129.99M | $ 10.62M | |
| Per Share Metrics | |||||
| Basic EPS | $ 0.23 | $ -0.38 | $ -0.48 | $ -0.86 | $ 0.07 |
| Diluted EPS | $ 0.22 | $ -0.38 | $ -0.48 | $ -0.86 | $ 0.07 |
| Weighted Average Shares Outstanding | 313.37M | 308.98M | 174.99M | 150.94M | 148.92M |
| Weighted Average Shares Outstanding (Diluted) | 324.81M | 308.98M | 176.14M | 150.94M | 151.82M |
Currency in USD

